Sign In
Buy XGN
$4.54
-0.280 (-5.81%)
At Close: Jun 03, 2026
AdaptHealth Corp. (AHCO) Reports Q1 Loss, Tops Revenue Estimates
02:45pm, Tuesday, 10'th May 2022 Zacks Investment Research
AdaptHealth Corp. (AHCO) delivered earnings and revenue surprises of -109.52% and 9.81%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
MacroGenics (MGNX) Reports Q1 Loss, Lags Revenue Estimates
09:15pm, Tuesday, 03'rd May 2022 Zacks Investment Research
MacroGenics (MGNX) delivered earnings and revenue surprises of -28.57% and 35.46%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Exagen Announces Five-Week Campaign for Lupus Awareness Month
04:00pm, Sunday, 01'st May 2022 GlobeNewswire Inc.
SAN DIEGO, May 01, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of a
Exagen to Announce First Quarter 2022 Financial Results on May 11, 2022
08:05pm, Monday, 25'th Apr 2022 GlobeNewswire Inc.
SAN DIEGO, April 25, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended March 31, 2022, af
Exagen to Announce First Quarter 2022 Financial Results on May 11, 2022
04:05pm, Monday, 25'th Apr 2022
SAN DIEGO, April 25, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended March 31, 2022, afte
Exagen Inc. to Participate in Investor Summit Group’s Q2 Conference
08:05pm, Wednesday, 20'th Apr 2022 GlobeNewswire Inc.
SAN DIEGO, April 20, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in Investor Summit Group’s Q2 Conf
Exagen Inc. Expands In-Network Access with Evolutions Healthcare Systems
12:25pm, Wednesday, 30'th Mar 2022 GlobeNewswire Inc.
SAN DIEGO, March 30, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® tests have entered into an in-network agre
Exagen Inc. (XGN) Q4 2021 Earnings Call Transcript
02:00am, Wednesday, 23'rd Mar 2022 The Motley Fool
XGN earnings call for the period ending December 31, 2021.
Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates
09:25pm, Tuesday, 22'nd Mar 2022 Zacks Investment Research
Exagen Inc. (XGN) delivered earnings and revenue surprises of 14.29% and 9.86%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Exagen Inc. (XGN) CEO Ron Rocca on Q4 2021 Results - Earnings Call Transcript
08:30pm, Tuesday, 22'nd Mar 2022
Exagen Inc. (XGN) CEO Ron Rocca on Q4 2021 Results - Earnings Call Transcript
Exagen Inc. Expands In-Network Benefit with Additional 22.7 Million Lives
08:06pm, Tuesday, 22'nd Mar 2022 GlobeNewswire Inc.
SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® tests will soon surpass 90 million lives a
Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates
06:48pm, Tuesday, 22'nd Mar 2022
Exagen Inc. (XGN) delivered earnings and revenue surprises of 14.29% and 9.86%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Exagen Announces New Rheumatoid Arthritis Scientific Advisory Board
08:05pm, Wednesday, 16'th Mar 2022 GlobeNewswire Inc.
SAN DIEGO, March 16, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the formation of its new Scientific Advisory Board (SAB
Myomo, Inc. (MYO) Reports Q4 Loss, Tops Revenue Estimates
10:35pm, Wednesday, 09'th Mar 2022 Zacks Investment Research
Myomo, Inc. (MYO) delivered earnings and revenue surprises of -6.12% and 34.36%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Exagen Inc. to Participate in the 2022 KeyBanc Capital Markets Life Sciences and MedTech Investor Forum
09:05pm, Wednesday, 09'th Mar 2022 GlobeNewswire Inc.
SAN DIEGO, March 09, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the KeyBanc Capital Markets Life S
